In this podcast interview, Dan Fisher, managing director and practice lead for IPM.ai, a division of Real Chemistry, explains how weekly data from 300 million patients can help brands assess a patient population, accelerate clinical trial recruitment, and optimize commercial outcomes.

Machine learning and artificial intelligence have emerged as key technologies for stitching together medical events and then predicting a diagnosis, even for conditions that are so rare no ICD-10 code exists. Once a de-identified rare or specialty disease patient is uncovered, IPM.ai enables clients to reach their top physicians directly, so they can prescribe a treatment-appropriate therapy or recommend a clinical trial. 

Fisher also discusses how IPM.ai works in cooperation with its sister organization, Swoop, to help reach and activate patient and physician audiences through healthcare advertising and a next best action engagement model, including for rare and specialty disorders.

Ai is an outstanding tool to help advance medical and business aspirations.

See omnystudio.com/listener for privacy information.